Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce announced the voting results from its Annual General and Special Meeting of Shareholders held on Monday, October 31 2022. A total of 16.55% of the issued and outstanding common shares of the Company were represented either in person or by proxy at the meeting.
On a vote by ballot, the following 4 nominees proposed by the Company were elected as Directors of Braxia Scientific to serve until the Company’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
| Director | For | % | Withheld | % |
| | | | |
| Roger McIntyre | 39,392,336 | 98.9 % | 442,621 | 1.1 % |
| Olga Cwiek | 39,669,971 | 99.6 % | 164,986 | 0.4 % |
| Leann Taylor | 39,382,703 | 98.9 % | 452,254 | 1.1 % |
| Jerry Habuda | 39,646,957 | 99.5 %
| 188,000 | 0.5 % |
In addition to the election of all nominees listed as directors in the management information circular, dated September 16, 2022 (the “Circular”), Braxia shareholders approved all other resolutions placed before the meeting. These included appointing DMCL as auditors for the Company for the ensuing year and approving an amendment to the Company’s stock option plan dated October 15, 2019 as set forth in the Circular.
About Braxia Scientific Corp
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal.